. AuerJ, HinterreiterM, AllingerS, KirchgattererA, KnoflachP.Severe pancytopenia after leflunomide in rheumatoid arthritis. Acta Med Austriaca2000; 27: 131–2.
2.
. Definitions and basic requirements for the use of terms for reporting adverse drug reactions (XIII): clinical pathology and general disorders. Pharmacoepidemiol Drug Saf1999; 8: 217–24.
3.
. NaranjoCA, BustoU, SellersEM, SandorP, RuizI, RobertsEA, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther1981; 30: 239–45.
4.
. BuchbinderR, HallS, SambrookPN, ChampionDG, HarknessA, LewisD, et al. Methotrexate therapy in rheumatoid arthritis: a life table review of 587 patients treated in community practice. J Rheumatol1993; 20: 639–44.
5.
. MorganSL, BaggotJE, VaughnWH, YoungPK, AustinJV, KrumdieckCL, et al. The effect of folic acid supplementation on the toxicity of low-dose methotrexate in patients with rheumatoid arthritis. Arthritis Rheum1990; 33: 9–18.
